Update Report of the ReSPECT-GBM Phase I/IIa Dose Escalation Trial of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma [rGBM] via Convection Enhanced Delivery (CED) (SNO 2023) - Nov 11, 2023 - Abstract #CTNI-50; Pres time: Nov 17, 2023; 07:30 PM - 09:30 PM; Location: Exhibit Hall A/B; "A single administration of 186RNL by CED in recurrent glioma patients is feasible, safe, and potentially effective in increasing overall survival when > 100Gy radiation is delivered to the tumor. A RP2D of 22.3mCi in 8.8mL was selected for patients with tumor size of ≤20mL in the planned Phase 2B."
P1/2 data • Brain Cancer • CNS Disorders • CNS Tumor • Epilepsy • Fatigue • Glioma • Oncology • Pain • Solid Tumor
|
|
Andrew J. Brenner; Joel Michalek; Melissa Moore; Marc Hedrick; Ande Bao; William T. Phillips; Toral R. Patel; Jeffrey S. Weinberg; John Floyd; Michael Youssef; Shiliang Huang; Norman LaFrance
|